Skip to main content
. 2018 Jul 19;8:10902. doi: 10.1038/s41598-018-27643-3

Figure 2.

Figure 2

MIRAT gene expression increases in a time and dose dependent manner. (a) MIRAT is upregulated under MEK inhibitor treatment with trametinib and increases over time. PCR (top left) and RT-qPCR analyses (top right) of MIRAT in D04 cells treated with 5 nM of the MEK inhibitor at indicated time points (0, 24, 48, 72 and 96 hours). RT-qPCR data is presented as the relative MIRAT expression normalized to GAPDH. Western blot analyses displaying signaling changes in D04 parental, drug-sensitive cells after MEK inhibitor treatment over time: p-ERK levels are reduced and recover over time; (b) Increasing doses of the MEK inhibitor trametinib correlate with MIRAT expression. PCR (left) and RT-qPCR analysis (right) of MIRAT were performed on cDNA from D04 cells with different concentrations of the MEK inhibitor (5 nM–1 mM) for 96 hours (Right). Western blot analyses displaying signaling changes in D04 parental, drug-sensitive cells after MEK inhibitor treatment at different doses. Cells show a dose dependent reduction of p-ERK.